September 1986


Arch Gen Psychiatry. 1986;43(9):899. doi:10.1001/archpsyc.1986.01800090089012

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Incorrect Phrasing in Text and Table Footnotes—  In the article titled "Dopamine Agonist Treatment of Schizophrenia With N-Propylnorapomorphine," published in the April Archives (1986;43:398-402), some text phrasing and table footnotes were incorrect. On page 398, column 1, in the introduction, the complete sentence beginning on line 8 should have read: "More recently, in controlled studies, apomorphine has been shown to reduce psychotic manifestations in schizophrenia, schizoaffective schizophrenia, and mania.3-7" Also, on page 399, for Table 2, footnote 1 should have read: "Mean change in scores derived as described in Table 1. Neuroleptic responders are those subjects who had an antipsychotic response to haloperidol of more than 50% (n = 5); the response to the dose of N-propylnorapomorphine producing the maximal change was compared with the maximal placebo response. Neuroleptic non-responders were those subjects who had less than a 50% response to haloperidol (n = 4); no significant effect of N-propylnorapomorphine occurred

First Page Preview View Large
First page PDF preview
First page PDF preview